TOPLINE: A 0.4 mg dose of aflibercept in infancy to treat retinopathy of prematurity (ROP) shows sustained efficacy and safety at 3 years of age, according to research presented at EURETINA 2024. No significant ocular or systemic safety concerns were identified during follow-up, and retinal vascularization appeared complete in 80% of eyes by age 2 …
